# Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development

**Authors:** Tao Wang, Shaad Essa Abedin, Jan Willem van der Laan

PMC · DOI: 10.3389/fonc.2025.1640377 · Frontiers in Oncology · 2025-07-17

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, FANCB (FA complementation group B) [NCBI Gene 2187] {aka FA2, FAAP90, FAAP95, FAB, FACB}
- **Diseases:** death (MESH:D003643), enterocolitis (MESH:D004760), adrenal insufficiency (MESH:D000309), cerebrovascular accidents (MESH:D020521), cancer (MESH:D009369), hypotension (MESH:D007022), myocarditis (MESH:D009205), hypophysitis (MESH:D000072659), breast cancer (MESH:D001943), bronchospasm (MESH:D001986), hemorrhage (MESH:D006470), toxicities (MESH:D064420)
- **Chemicals:** paclitaxel (MESH:D017239), pembrolizumab (MESH:C582435), cetuximab (MESH:D000068818), polatuzumab vedotin (MESH:C000600736), bevacizumab (MESH:D000068258)
- **Species:** Caldithrix palaeochoryensis (species) [taxon 650508], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310743/full.md

---
Source: https://tomesphere.com/paper/PMC12310743